Annual vaccination against influenza A and B viruses is recommended in the US for everyone ≥6 months old without a contraindication.1,2 Influenza vaccines available in the US for the 2025-2026 season are listed in Table 2.
COMPOSITION — All influenza vaccines available in the US this season are trivalent: they contain two influenza A virus antigens and one influenza B virus antigen (see Table 1).3 Influenza A viruses are the primary cause of...
- Acoltremon (Tryptyr) for Dry Eye Disease
- A New Heart Failure Indication for Finerenone (Kerendia)
- Inclisiran (Leqvio) Monotherapy for LDL-Cholesterol Reduction
- Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic
- In Brief: Embryotoxicity REMS Removal for Endothelin Receptor Antagonists
- Sunvozertinib (Zegfrovy) for NSCLC (online only)
ISSUE
The FDA has approved Xifyrm (Azurity) and Qamzova (Nanjing Delova), two new intravenous (IV) formulations of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam, for use alone or in combination with non-NSAID analgesics for treatment of moderate to severe pain in adults. Anjeso, the first IV formulation of meloxicam, was discontinued in 2022 for commercial reasons.1
NONOPIOIDS FOR PAIN – Use of oral or IV acetaminophen or NSAIDs with opioids has been associated with less postoperative pain and opioid consumption compared to use of opioids alone.2 A combination of an NSAID and acetaminophen may be an alternative to opioids.3,4
Meloxicam – Meloxicam has COX-2 selectivity in vitro, which decreases at higher dosages; it has been associated with lower rates of some GI-related adverse effects than nonselective NSAIDs, and it is …